Abstract
Background: Irreversible electroporation (IRE) is being studied as a treatment option for patients with locally advanced pancreatic cancer (PC). Our laboratory has shown that combination of IRE with immunotherapy optimizes the local and distant effects of IRE treatment. Post-translational protein modification by small ubiquitin-like modifier (SUMO ) is upregulated in cancer and is important for the function of immune checkpoints. TAK-981 is a novel inhibitor of SUMO ylation that inhibits PC cell proliferation and also upregulates type I interferon responses, boosting anti-tumor immunity. We hypothesized that there would be synergistic effects of combining IRE with TAK-981 treatment.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
